The diagnosis of ET requires a comprehensive evaluation, including peripheral blood smear analysis, bone marrow biopsy, and genetic testing for mutations of JAK2, CALR, or MPL. Cytoreductive therapy or treatment comprising antiplatelet agents, depending on the risk stratification, is administered to reduce the thrombotic and hemorrhagic risks [9]. Here, JAK2 is linked to essential thrombocythemia.